Bain Capital Life Sciences Investors, LLC
CIK 0001703031 · BOSTON, MA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.68B
2026 Q2
Positions
21
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
87.9%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
KLRA
KAILERA THERAPEUTICS INC
29.6%
HTFL
HEARTFLOW INC
14.7%
NAMS
NEWAMSTERDAM PHARMA COMPANY
7.7%
SVRA
SAVARA INC
6.4%
ALKS
ALKERMES PLC
6.0%
SLDB
SOLID BIOSCIENCES INC
5.8%
PHVS
PHARVARIS N V
5.5%
OLMA
OLEMA PHARMACEUTICALS INC
5.3%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.